MAPT and Alzheimer disease: In a manner similar to amyloid-targeting therapies showing important downstream decreases in soluble ptau biomarkers in CSF and blood [4, 94], it is important for tau-targeting therapies to show they can affect downstream events and most notably one of the key features of AD, neurodegeneration.